Compare · EVLO vs KLDO
EVLO vs KLDO
Side-by-side comparison of Evelo Biosciences Inc. (EVLO) and Kaleido Biosciences Inc. (KLDO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EVLO focuses on Biotechnology: Pharmaceutical Preparations, while KLDO focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- EVLO is the larger of the two at $243.2M, about 3.3x KLDO ($74.1M).
- Both have 4 recent analyst ratings on file.
- Company
- Evelo Biosciences Inc.
- Kaleido Biosciences Inc.
- Price
- $0.32-13.60%
- $0.30-0.23%
- Market cap
- $243.2M
- $74.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2019
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 4
Evelo Biosciences Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Kaleido Biosciences Inc.
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Latest EVLO
- Alltrna Announces Updates to Its Board of Directors
- SEC Form EFFECT filed by Evelo Biosciences Inc.
- SEC Form 15-12G filed by Evelo Biosciences Inc.
- SEC Form S-8 POS filed by Evelo Biosciences Inc.
- SEC Form S-8 POS filed by Evelo Biosciences Inc.
- Evelo Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form POS AM filed by Evelo Biosciences Inc.
- SEC Form 25-NSE filed by Evelo Biosciences Inc.
- SEC Form DEFA14A filed by Evelo Biosciences Inc.
- SEC Form DEF 14A filed by Evelo Biosciences Inc.
Latest KLDO
- SEC Form SC 13G/A filed by Kaleido Biosciences Inc. (Amendment)
- SEC Form 15-12B filed by Kaleido Biosciences Inc.
- SEC Form EFFECT filed by Kaleido Biosciences Inc.
- SEC Form S-8 POS filed by Kaleido Biosciences Inc.
- SEC Form S-8 POS filed by Kaleido Biosciences Inc.
- SEC Form S-8 POS filed by Kaleido Biosciences Inc.
- SEC Form POS AM filed by Kaleido Biosciences Inc.
- SEC Form 25 filed by Kaleido Biosciences Inc.
- The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
- 12 Health Care Stocks Moving In Thursday's After-Market Session